These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22382881)

  • 21. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST; Park JY; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    Jpn J Clin Oncol; 2010 Nov; 40(11):1031-6. PubMed ID: 20534685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
    J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel in the management of advanced pancreatic cancer.
    Lopes G; Rocha Lima CM
    Semin Oncol; 2005 Apr; 32(2 Suppl 4):S10-23. PubMed ID: 16015551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
    Ngeow J; Toh CK
    Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of drug therapy of lung cancer in Hungary].
    Moldvay J; Rokszin G; Abonyi-Tóth Z; Katona L; Kovács G
    Magy Onkol; 2013 Mar; 57(1):33-8. PubMed ID: 23573520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
    Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
    Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.
    Natsume T; Watanabe J; Horiuchi T; Kobayashi M
    Anticancer Res; 2006; 26(2A):1145-51. PubMed ID: 16619516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
    Lilenbaum R; Socinski MA; Altorki NK; Hart LL; Keresztes RS; Hariharan S; Morrison ME; Fayyad R; Bonomi P
    J Clin Oncol; 2006 Oct; 24(30):4825-32. PubMed ID: 17050867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel followed by gemcitabine and irinotecan in solid tumors.
    Rocha Lima CM; Urbanic JJ; Sherman CA; Brescia FJ; Green MR
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):37-45. PubMed ID: 11221020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chemotherapy for advanced non-small cell lung cancer].
    Ueoka H
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):770-6. PubMed ID: 15984514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
    Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
    Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with docetaxel in the treatment of gastric cancer.
    Philip PA
    Semin Oncol; 2005 Apr; 32(2 Suppl 4):S24-38. PubMed ID: 16015552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
    Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New perspectives in the management of pancreas cancer.
    Haller DG
    Semin Oncol; 2003 Aug; 30(4 Suppl 11):3-10. PubMed ID: 14506598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for the use of gemcitabine in breast cancer (Review).
    Silvestris N; D'Aprile M; Andreola G; Locopo N; Marini L; Crucitta E; De Lena M; Lorusso V
    Int J Oncol; 2004 Feb; 24(2):389-98. PubMed ID: 14719116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
    Mercalli A; Sordi V; Formicola R; Dandrea M; Beghelli S; Scarpa A; Di Carlo V; Reni M; Piemonti L
    Br J Cancer; 2007 May; 96(9):1358-67. PubMed ID: 17426706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.